SCHEMBL4969172

SCHEMBL4969172

O=C(NCC1CCCCC1)Nc1ccc2ncccc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 4/20 0.70
POLB P06746 3/20 0.64
NPC1 O15118 2/20 0.64
MEN1 O00255 1/20 0.64
MAPT P10636 1/20 0.64
KMT2A Q03164 1/20 0.64
EPHX2 P34913 2/20 0.57
CCNE1 P24864 1/20 0.55
CDK2 P24941 1/20 0.55
CDK5 Q00535 1/20 0.55
NAMPT P43490 3/20 0.53
PABPC1 P11940 1/20 0.51
P2RX7 Q99572 1/20 0.51
PRMT3 O60678 2/20 0.50
ROCK2 O75116 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4965304 0.91 EPHX1 (0.70) EPHX1POLBNPC1MEN1MAPT
SCHEMBL12196146 0.83 EPHX1 (1.00) EPHX1POLBNPC1MEN1MAPT
SCHEMBL5527183 0.82 NPC1 (0.68) EPHX1POLBNPC1MEN1MAPT
SCHEMBL4964208 0.81 NPC1 (0.55) EPHX1POLBNPC1MEN1MAPT
SCHEMBL31054249 0.79 NPC1 (1.00) POLBNPC1MEN1MAPTKMT2A
SCHEMBL651929 0.79 NPC1 (1.00) POLBNPC1MEN1MAPTKMT2A
SCHEMBL23758889 0.79 NPC1 (0.63) POLBNPC1MEN1MAPTKMT2A
SCHEMBL4964213 0.78 ALDH1A1 (0.59) EPHX1NPC1MAPTP2RX7ALDH1A1
SCHEMBL17898130 0.78 NPC1 (0.74) POLBNPC1MEN1MAPTKMT2A
SCHEMBL4962880 0.78 PRMT3 (0.72) EPHX1EPHX2PRMT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101351495-A fatty acid amide hydrolase inhibitors ORGANON NV (NL) 2009-01-21 CN disclosed
EP-1969051-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. Organon (NL) 2008-09-17 EP disclosed
WO-2007079180-A2 INHIBITORS OF FATTY ACID AMIDE HYDROLASE N.V. ORGANON (NL) 2007-07-12 WO disclosed
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE KADMUS PHARMACEUTICALS, INC. (US) 2007-07-05 US disclosed
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE KADMUS PHARMACEUTICALS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155747-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ABHD6 EPHX1 84/4885POLB 2152/4885NPC1 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.